Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.33 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485562 | 0.83 | CCR3 (0.66) | CCR3KCNH2CCR2CACNA1HKMT2A | |
| SCHEMBL7104200 | 0.80 | CCR3 (0.70) | CCR3KCNH2CCR2HRH1TAOK1 | |
| SCHEMBL5619221 | 0.80 | CCR3 (0.70) | CCR3KCNH2CCR2HRH1TAOK1 | |
| SCHEMBL4474929 | 0.79 | CCR2 (0.48) | CCR3KCNH2CCR2HRH1P2RX7 | |
| SCHEMBL4484994 | 0.78 | CCR3 (0.45) | CCR3KCNH2CCR2HRH1CACNA1H | |
| SCHEMBL4487731 | 0.78 | CCR3 (0.63) | CCR3KCNH2CACNA1HKMT2A | |
| SCHEMBL4677378 | 0.76 | CCR3 (0.65) | CCR3KCNH2CCR2CACNA1HKMT2A | |
| SCHEMBL13631396 | 0.76 | CCR3 (0.70) | CCR3KCNH2CCR2CACNA1HKMT2A | |
| SCHEMBL13631405 | 0.75 | CCR3 (0.42) | CCR3KCNH2CCR2HRH1EPHA2 | |
| Hydrochloric Acid SCHEMBL4488350 | 0.75 | CCR3 (0.69) | CCR3KCNH2CCR2CACNA1HKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | CCR3 1/4885KCNH2 2405/4885CCR2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.